News | Health & Safety
23 Jun 2017 13:51
NZCity News
NZCity CalculatorReturn to NZCity

  • Start Page
  • Personalise
  • Sport
  • Weather
  • Olympic Games
  • Ski Report
  • Finance
  • Shopping
  • Jobs
  • Horoscopes
  • Lotto Results
  • Photo Gallery
  • Site Gallery
  • TVNow
  • Dating
  • SearchNZ
  • NZSearch
  • Crime.co.nz
  • RugbyLeague
  • Make Home
  • About NZCity
  • Contact NZCity
  • Your Privacy
  • Advertising
  • Login
  • Join for Free

  •   Home > News > Health & Safety

    Pacific Edge gets $3m extension to grant

    Pacific Edge has won a two-year extension to its research grant to fund the development of its Cxbladder products for bladder cancer detection.


    Pacific Edge has won a two-year extension to its Callaghan Innovation research grant to fund the development of its Cxbladder diagnostic suite of products for bladder cancer detection.

    The Dunedin-based firm has received up to $3 million of extra funding for research and development spread over two years, on top of an initial three-year grant of $4.5m it received in 2014, it said in a statement.

    Since the first grant was awarded, Pacific Edge has launched three new products to add to the original bladder cancer diagnostics test, with each test addressing different clinical needs.

    The shares rose 3.5 per cent to 59 cents.

    "Investment into research and development is a major focus for Pacific Edge and we are continually looking at how we can provide better and more targeted diagnostic tools for clinicians and their patients," chief executive David Darling said.

    "The Growth Grant supplements Pacific Edge's own investment into R&D and will enable us to bring new innovations through into new products and product improvements."

    The company raised $8 million in February through a share placement to institutional investors to shore up its balance sheet as it ramps up efforts to lift commercial growth.

    It started making commercial sales in 2013 and at the time was targeting $100m in gross revenue within five years.

    The recent capital raise left it with $9m of cash to fund its immediate growth needs, and when reporting its first half result in November it signalled plans to have all four Cxbladder products fully launched in the US by 2018.

    # (BusinessDesk receives funding from Callaghan Innovation to help cover the commercialisation of innovation.)


    NZN




    © 2017 NZN, NZCity


     Other Health & Safety News
     22 Jun: Call for more to avoid sudden infant death
     21 Jun: Flags raised over antipsychotic drug
     21 Jun: Doctors back med students' loan complaint
     19 Jun: Wrong vaccine given to 15-month old
     18 Jun: Steve Scalise: Republican congressman 'more responsive', recovering in hospital after being shot at baseball game
     17 Jun: Why TV dinners can be bad for you
     16 Jun: Death rates after surgery high among poor
     Top Stories

    RUGBY RUGBY
    British and Irish Lions penpix More...


    BUSINESS BUSINESS
    Vector signs deal in Alice Springs More...



     Today's News

    Business:
    Vector signs deal in Alice Springs 13:47

    Entertainment:
    Carrie Fisher's drug use was "not news" to her brother Todd Fisher 13:27

    Cricket:
    Bracewell misses out on cricket contract 13:27

    Rugby League:
    Sharks' Origin stars "certainties" for NRL 13:07

    Entertainment:
    Taylor Swift reportedly spent Father’s Day (18.06.17) in London with her boyfriend Joe Alwyn and his family 12:57

    Entertainment:
    Kim Kardashian West has branded Kanye West as her "best friend" 12:27

    Rugby League:
    New Cowboy Martin to miss Penrith NRL game 12:27

    Entertainment:
    Steve Carell is a “fan” of Kristen Wiig 11:57

    Politics:
    PM and Labour wounded after a brutal week 11:57

    Entertainment:
    Dame Helen Mirren thinks things have “changed substantially” for women in the film and television industry 11:27


     News Search






    Power Search


    © 2017 New Zealand City Ltd